Pixium Vision announces its financial results for 2021 and provides a business update. The 2021 financial statements were approved by Pixium Vision’s Board of Directors at its meeting on 17 February 2022.
- Cash position on 31 December 2021: €14.5 million
- Cash runway to end of Q4 2022
- Clinical development, activating multiple clinical sites and successfully implanting patients enrolled in our PRIMAvera pivotal study
Lloyd Diamond, CEO of Pixium Vision commented “In 2021, we continued to deliver on our promises, and we progressed significantly on our journey to create a world of bionic vision for those who have lost their sight. In spite of the Covid-19 pandemic, we continued to make strong progress on many fronts throughout 2021, progressing through our PRIMAvera pivotal study, the last step of clinical development in Europe and continuing to strengthen our presence in the US in anticipation of increasing clinical development in this key market. We are well positioned drive the Prima System through these important stages, having successfully extended our cash runway to end of 2022.”